Inventor · disambiguated record
Lishan Chen
Also filed as: CHEN LISHAN
3 granted patents·18 pending applications·4 citations·filing 2005–2023
59Inventor score
Files withNASTECH PHARM CO7MOLECULAR AXIOM LLC3CHEN LISHAN2MARINA BIOTECH INC2ULTRAGENYX PHARMACEUTICAL INC2
Top patents by PatentIndex Score
21 records- 0169US8299236B2Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cellsCHEN LISHAN·Filed 2008·Granted Oct 30, 2012·3 cites·13 claims
- 0265US11304389B2Sub-irrigation bed and cultivation apparatusFUJIAN SANAN SINO SCIENCE PHOTOBIOTECH CO LTD·Filed 2019·Granted Apr 19, 2022·1 cites·10 claims
- 0365US2015252369A1Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cellsMARINA BIOTECH INC·Filed 2014·Application pending·0 cites
- 0464US2006122137A15'-methylpyrimidine and 2'-O-methyl ribonucleotide modified double-stranded ribonucleic acid moleculesNASTECH PHARM CO·Filed 2005·Application pending·0 cites
- 0563US2008261304A1Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cellsNASTECH PHARM CO·Filed 2008·Application pending·0 cites
- 0659US2024392293A1Compositions and methods for modulating kras expressionMOLECULAR AXIOM LLC·Filed 2022·Application pending·0 cites
- 0757US2025297251A1Certain dux4 inhibitors and methods of use thereofULTRAGENYX PHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 0857US2024182894A1Compositions and methods for modulating sos gene expressionsMOLECULAR AXIOM LLC·Filed 2022·Application pending·0 cites
- 0956US2024409931A1Compositions and methods for modulating nlrp3 or nlrp1 expressionMOLECULAR AXIOM LLC·Filed 2022·Application pending·0 cites
- 1055US2006014289A1Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cellsNASTECH PHARM CO·Filed 2005·Application pending·0 cites
- 1153US8940857B2Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cellsAHMADIAN MOHAMMAD·Filed 2010·Granted Jan 27, 2015·0 cites·9 claims
- 1252US2016206749A1Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cellsMARINA BIOTECH INC·Filed 2015·Application pending·0 cites
- 1351US2009018097A1Modification of double-stranded ribonucleic acid moleculesMDRNA INC·Filed 2006·Application pending·0 cites
- 1450US2010129460A1Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeuticsNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 1550US2023348906A1Dux4 inhibitors and methods of use thereofULTRAGENYX PHARMACEUTICAL INC·Filed 2021·Application pending·0 cites
- 1650US2010113332A1Method of treating an inflammatory disease by double stranded ribonucleic acidNASTECH PHARM CO·Filed 2005·Application pending·0 cites
- 1744US2007275923A1CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERYNASTECH PHARM CO·Filed 2007·Application pending·0 cites
- 1840US2006040882A1Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cellsCHEN LISHAN·Filed 2005·Application pending·0 cites
- 1939US2013072424A1Compounds and methods for peptide ribonucleic acid condensate particles for rna therapeuticsADAMI ROGER C·Filed 2012·Application pending·0 cites
- 2038US2006035815A1Pharmaceutical compositions for delivery of ribonucleic acid to a cellNASTECH PHARM CO·Filed 2005·Application pending·0 cites
- 2130US2017081667A1Nucleic acid that inhibits expression of irf5KYOWA HAKKO KIRIN CO LTD·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lishan Chen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →